WARNING: QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH
can prolong the QT interval. Torsades de pointes and sudden death have occurred in patients receiving CAPRELSA. Do not use CAPRELSA in patients with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Correct hypocalcemia, hypokalemia and/or hypomagnesemia prior to CAPRELSA administration. Monitor electrolytes periodically. Avoid drugs known to prolong the QT interval. Only prescribers and pharmacies certified with the restricted distribution program are able to prescribe and dispense CAPRELSA [see Warnings and Precautions (5.1, 5.15)].
CAPRELSA tablets for daily oral administration are available in two dosage strengths, 100 mg and 300 mg, containing 100 mg and 300 mg of vandetanib, respectively.
CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Use of CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of CAPRELSA.
Published Studies Related to Caprelsa (Vandetanib)
Vandetanib for the treatment of medullary thyroid carcinoma. 
CONCLUSIONS: Vandetanib prolongs PFS but has not been shown to improve OS.
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally
advanced medullary thyroid cancer. 
CONCLUSION: Vandetanib has been shown to be more effective than placebo in the
Vandetanib: in medullary thyroid cancer. 
Vandetanib, an orally active, small-molecule, multitargeted tyrosine kinase
inhibitor, demonstrates potent inhibitory activity against vascular endothelial
growth factor receptor (VEGFR)-2 and -3, epidermal growth factor receptor (EGFR)
and the rearranged during transfection (RET) tyrosine kinase receptor...
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer
after prior therapy with an epidermal growth factor receptor tyrosine kinase
inhibitor: a randomized, double-blind phase III trial (ZEPHYR). 
chemotherapy regimens... CONCLUSION: The study did not demonstrate an overall survival benefit for
Vandetanib in patients with locally advanced or metastatic medullary thyroid
cancer: a randomized, double-blind phase III trial. 
patients with advanced hereditary MTC... CONCLUSION: Vandetanib demonstrated therapeutic efficacy in a phase III trial of
Reports of Suspected Caprelsa (Vandetanib) Side Effects
Electrocardiogram QT Prolonged (15),
Blood Pressure Increased (13),
Joint Swelling (8),
Arthralgia (8), more >>
Page last updated: 2014-11-30